Illumina Inc. and Merck & Co. Inc. are partnering to commercialize tests identifying genetic mutations used in the assessment of homologous recombination deficiency (HRD). Patients whose tumors are HRD-positive may be eligible for targeted chemotherapy treatment by a class of precision medicines called PARP inhibitors. The companies will develop tests utilizing Illumina's Trusight Oncology 500 assay for genomic profiling, which is designed to identify 523 known and emerging tumor biomarkers. Read More
The question of whether an artificial intelligence (AI) algorithm can be an inventor has been making the rounds in the past couple of years, and the question came up again in the U.S. District Court for the Eastern District of Virginia. Stephen Thaler, who developed the Device for the Autonomous Bootstrapping of Unified Sentience (DABUS) algorithm that has been credited with two inventions, failed to persuade the court that an algorithm qualifies as an “individual,” and thus patents must still be assigned to humans, at least where the U.S. Patent and Trademark Office is concerned. Read More
LONDON – Breath biopsy specialist Owlstone Medical Ltd. closed a $58 million oversubscribed series D, bringing the total raised by the company since its formation in 2016 to over $150 million. The money will support further development of tests for lung cancer, liver disease and respiratory disease, and of a new class of diagnostics, which rather than measuring endogenous markers of disease, involve administering chemical probes and assessing how they are metabolized. Read More
Centaur Diagnostics Inc. herded up interest in its gamified system for labeling medical data for use in artificial intelligence (AI) applications. The Boston-based company raised $12 million in a series A round that will help Centaur build out its crowdsourced system for labeling medical images, videos, text and audio recordings. The round brings the company’s funds raised to date to $15 million. Matrix Partners led the charge along with Accel Partners, Global Founders Capital, Susa Ventures, and Y Combinator. Read More
TORONTO – Neupath Health Inc. and Cynergi Health Partners have signed a memorandum of understanding that could see Cynergi’s virtual reality (VR) software combined with Neupath’s remote pain management platform. The platform is expected to benefit from the therapeutic potential of Austin, Texas-based Cynergi’s Rilaxta VRx to lower patient anxiety and perception of pain as they walk through restful, VR-created landscapes. “We don’t see another group taking a similar, holistic approach to pain management that we are,” Neupath CEO Grant Connelly told BioWorld. Read More
Med-tech firms raising money in public or private financings, including: Definitive Healthcare, Emulate, Hancock Jaffe Laboratories, Windgap Medical. Read More
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Active Implants, Antylia Scientific, Avantor, Cardiogenics, Covidgenic, Dnanudge, Fresenius Helios, Geistlich Pharma, Inanobio, Innovative Medical Engineering Technologies, Masterflex Bioprocessing, Natera, NRG Oncology, Vivolta. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Medtronic, Siemens Healthineers, Transmedics. Read More
